BusinessEmergent BioSolutions Reports First Quarter 2018 Financial ResultsBy Nasdaq OMXMay 3, 2018, 8:30 PM UTC
BusinessEmergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin ProgramBy Nasdaq OMXFeb 28, 2018, 11:45 AM UTC
BusinessEmergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 GuidanceBy Nasdaq OMXNov 2, 2017, 8:15 PM UTC
BusinessEmergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017By Nasdaq OMXOct 19, 2017, 11:00 AM UTC
BusinessEmergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 GuidanceBy Nasdaq OMXAug 3, 2017, 8:15 PM UTC
BusinessEmergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be AvailableBy Nasdaq OMXMay 11, 2017, 11:00 AM UTC
BusinessEmergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 GuidanceBy Nasdaq OMXMay 4, 2017, 8:16 PM UTC
BusinessEmergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 GuidanceBy Nasdaq OMXMay 4, 2017, 8:16 PM UTC
